PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 1, OPEN LABEL, FIXED SEQUENCE STUDY TO ESTIMATE THE 
EFFECT OF MULTIPLE DOSE PF-06650833 ON THE PHARMACOKINETICS OF 
SINGLE DOSE ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE 
PARTICIPANTS
Study Intervention Number: PF-06650833
Study Intervention Name: N/A
US IND Number:EudraCT Number: N/A
ClinicalTrials.gov ID: N/A
Protocol Number: B7921026
Phase: 1
Brief Title: A Phase 1 Drug-Drug Interaction Study of PF-06650833 With Oral 
Contraceptives in Healthy Female Participants
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.
CCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date
Original protocol 29 July 2021

PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....7
1. PROTOCOL  SUMMARY.....................................................................................................8
1.1. Synopsis .................................................................................................................. ..8
1.2. Schema .................................................................................................................... 10
1.3. Schedule of Activities .............................................................................................11
2. INTRODUCTION ...............................................................................................................1 3
2.1. Study R ationale .......................................................................................................13
2.2. Background .............................................................................................................14
2.2.1. Nonclinical Pharmacology..........................................................................142.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................142.2.3. Nonclinical Safety ......................................................................................152.2.4. Clinical Overview.......................................................................................15
2.3. Benefit/Risk Assessment.........................................................................................17
2.3.1. Risk Assessment .........................................................................................182.3.2. Benefit Assessment.....................................................................................192.3.3. Overall Benefit/Risk Conclusion................................................................19
3. OBJECTIVES AND ENDPOINTS .....................................................................................194. STUDY DESIGN................................................................................................................ .19
4.1. Overall Design.........................................................................................................194.2. Scientific Rationale for Study Design.....................................................................20
4.2.1. Diversity of St udy Popul ation ....................................................................20
4.2.2. Choice of Contraception/Barrier Requirements .........................................20
4.3. Justification for Dose ..............................................................................................21
4.4. End of Study Definition ..........................................................................................21
5. STUDY POPULATION ......................................................................................................21
5.1. Inclusion Criteria.....................................................................................................22
5.2. Exclusion Criteria....................................................................................................235.3. Lifestyle Cons iderations..........................................................................................26
5.3.1. Meals and Dietary Restrictions...................................................................26CCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 45.3.2. Caffeine, Alcohol, and Tobacco .................................................................27
5.3.3. Activity .......................................................................................................27
5.3.4. Contracepti on
..............................................................................................27
5.4. Screen Failures ........................................................................................................28
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................28
6.1. Study  Intervention(s) Administered ........................................................................28
6.1.1. Administration ............................................................................................28
6.1.2. Medical Devices .........................................................................................29
6.2. Preparation, Handling, Storage, and Accountability ...............................................29
6.2.1. Preparation and Dispensing ........................................................................30
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................30
6.3.1. Allocation to Study Intervention ................................................................30
6.3.2. Breaking the Blind ......................................................................................30
6.4. Study  Intervention Compliance ................................ ................................ ............... 30
6.5. Dose Modification ...................................................................................................30
6.6. Continued Access to Study  Intervention After the End of the Study ......................31
6.7. Tre atment of Overdose ............................................................................................31
6.8. Concomitant Therapy ..............................................................................................31
6.8.1. Rescue Medicine .........................................................................................32
7. DI SCONT INUAT ION OF STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................32
7.1. Discontinuation of Study  Intervention ....................................................................32
7.1.1. L iver Injury .................................................................................................32
7.1.2. ECG Changes ..............................................................................................32
7.1.3. Potenti al Cases of Acute Kidney Injury .....................................................33
7.1.4. Pregnancy ...................................................................................................33
7.1.5. L aboratory  Abnormalities ...........................................................................33
7.2. Participant Discontinuation/Withdrawal From the Study .......................................34
7.2.1. Withdrawal of Consent ................................ ................................ ............... 35
7.3. L ost to Follow up ....................................................................................................35
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ............................... 36
8.1. Efficacy  Assessments ..............................................................................................37

PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 58.2. Safety Assessments .................................................................................................37
8.2.1. Physical Examinations................................................................................378.2.2. Vital Signs ..................................................................................................378.2.3. Electrocardiograms.....................................................................................388.2.4. Clinical Safety La boratory Asse ssments ....................................................39
8.2.5. COVID-19 Specific Assessments...............................................................398.2.6. Pregnancy Testing ......................................................................................39
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................40
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......40
8.3.1.1. Reporting SAEs to Pfizer Safety...............................................418.3.1.2. Recording Nonserious AEs and SAEs on the CRF...................41
8.3.2. Method of Detecting AEs and SAEs ..........................................................418.3.3. Follow-Up of AEs and SAEs......................................................................418.3.4. Regulatory Reporting Requirements for SAEs...........................................428.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................42
8.3.5.1. Exposure During Pregnancy......................................................428.3.5.2. Exposure During Breastfeeding ................................................448.3.5.3. Occupational Exposure .............................................................44
8.3.6. Cardiovascular and Death Events...............................................................448.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................44
8.3.8. Adverse Events of Special Interest.............................................................44
8.3.8.1. Lack of Efficacy........................................................................45
8.3.9. Medical Device Deficiencies......................................................................458.3.10. Medication Errors .....................................................................................45
8.4. Pharmacokinetics ....................................................................................................46
8.7. Immunogenicity Assessments .................................................................................47
CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 68.8. Health Economics ...................................................................................................47
9. STATISTICAL CONSIDERATIONS ................................................................................47
9.1. Statistical Hypotheses .............................................................................................479.2. Analysis Sets ...........................................................................................................489.3. Statistical Analyses .................................................................................................48
9.3.1. Pharmacokinetic Analyses..........................................................................489.3.2. Safety Analys es ..........................................................................................49
9.3.2.1. Electrocardiogram Analyses......................................................50
9.4. Interim Analyses .....................................................................................................50
9.5. Sample Size Determination.....................................................................................51
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................53
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............53
10.1.1. Regulatory and Ethical Considerations ....................................................53
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................53
10.1.2. Financial Disclosure .................................................................................5410.1.3. Informed Consent Process ........................................................................5410.1.4. Data Protection .........................................................................................5510.1.5. Committees Structure ...............................................................................55
10.1.5.1. Data Monitoring Committee ...................................................55
10.1.6. Dissemination of Clinical Study Data ......................................................5510.1.7. Data Qualit y Assurance ............................................................................57
10.1.8. Source Documents....................................................................................5810.1.9. Study and Site Start and Closure ..............................................................5810.1.10. Publication Policy...................................................................................5910.1.11. Sponsor’s Qualified Medical Personnel .................................................60
10.2. Appendix 2: Clinical Laboratory Tests .................................................................6110.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................63
10.3.1. Definition of AE .......................................................................................63CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 710.3.2. Definition of an SAE ................................................................................64
10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................65
10.3.4. Reporting of SAEs....................................................................................69
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................70
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................7010.4.2. Female Participant Reproductive Inclusion Criteria.................................7010.4.3. Woman of Childbearing Potential ............................................................7010.4.4. Contraception Methods.............................................................................71
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments 
and Study Intervention Rechallenge Guidelines .......................................................74
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................7610.8. Appendix 8: Abbreviations ...................................................................................78
11. REFERENCES ................................................................................................................. .83
LIST OF TABLES
Table 1. Study De sign and Treatments...................................................................20
Table 2. Plasma Pharmacokinetic Parameter Definitions.......................................49Table 3. Safety QTc Assessment ............................................................................50Table 4. Confidence Intervals Regarding the Effect of PF-06650833 on 
AUC
last of OC............................................................................................51
Table 5. Confidence Intervals Regarding the Effect of PF-06650833 on C max
of OC ........................................................................................................52
Table 6. Protocol Required Safety Laboratory Assessments..................................62CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 81. PROTOCOL SUMMARY 
1.1. Synopsis A Phase 1, open label, fixed sequence study to estimate the effect of multiple dose 
PF-06650833 on the pharmacokinetics of single dose oral contraceptive steroids in healthy female participants.
Brief Title: A Phase 1 Drug-Drug Interaction Study of PF-06650833 With Oral 
Contraceptives in Healthy Female Participants
RationaleThis study will evaluate the effect of PF-06650833 on pharmacokinetics of OC steroids, in 
order to select appropriate contraception requirements in Phase 2 studies.  
 
 
Objectives and Endpoints
Objectives Endpoints
Primary: Primary: 
•To estimate the effect of multiple oral doses of 
PF-06650833 on the PK of a single dose of a 
combination OC in healthy female participants.•Cmaxand AUC lastof EE and LN.
Secondary: Secondary: 
•To evaluate the saf ety of PF- 06650833 when 
co-administered with a single dose of a combination OC in healthy female participants.•Safety: laboratory tests, AEs reporting and vital 
signs.
Tertiary/Exploratory: Tertiary/Exploratory: 
•To characterize the PK of a single dose of a 
combination OC with or without PF-06650833in healthy female participants.•T
max, and if data permit CL/F, t ½and AUC inf, of 
EE and LN.
Overall Design
Brief SummaryThis is a Phase 1, fixed-sequence, multiple-dose, open-label study of the effect of multiple 
dose PF-06650833 on single dose OC PK in healthy female participants. The study will consist of 2 periods in a single fixed sequence. Participants will be screened within 28 days of the first dose of investigational product in Period 1. Participants will report to the CRU the CCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 9day prior to Day  1 dosing in Period 1. Participants will remain in the CRU for a total of 
16days and 15 nights. There will be no washout period.
PF-
06650833 is not expected to provide an y clinical benefit to health y participants. This 
study  is designed primarily  to generate
safet y, tolerability , and PK data for further clinical 
development .
Number of Participants
Approximately  10participants will be enrolled to study  intervention .
Note: 
“Enrolled ”means a participant ’s, or his or her legall y authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screening . A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in an y stud y activ ity after screening .Potential 
participants who are screened for the purpose of determining eligibility  for the study , but do 
not participate in the study, are not considered enrolled, unless otherwise specified b y the 
protocol.
Intervention Groups and Dur ation
The current study  will use a PF -
06650833 dose of 400 mg MR QD. This is the highest dose 
of PF -06650833 planned for use in future efficacy  and safet y trials.
On Period 1 Day  1, participants will be dosed with a single administration of OC in the form 
of 1 PORTI A®(EE and LN) or equivalent tablet, orally . OC (EE and LN) PK will then be 
assessed at pre -dose and over 48 hours, post OC dosing. Period 1 will be immediately  
followed b y Period 2 with no washout, in which participants will be dosed orally with
PF-06650833 400 mg MR QD for 9 day s followed by  administration of a single dose of OC 
on the morning of Day  10. OC PK will be assessed at pre -dose and for 48 hours following 
OC dosing. The 48 hours post OC dose PK sample must be collected prior to receivi ng first 
dose of PF -06650833. On Day  10, the morning dose of PF -06650833 and the single OC dose 
will be administered simultaneously within 5 minutes. Dosing with PF -06650833 
400mgPOQD will continue until Day  11.
Data Monitoring Committee or Other Independent Oversight Committee
No
Statistical Methods
To assess an y effect of PF -06650833 on EE or LN exposures, natural log transformed 
AUC lastand C maxwill be anal yzed using a mixed effects model with treatment as a fixed 
effect and particip ant as a random effect. Estimates of the adjusted mean differences 
(Test -Reference) and corresponding 90% CIs will be obtained from the model and will be 

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 10exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) 
and 90% C Is for the ratios .
1.2.Schema

PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 111.3. Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evalua tions or 
assessments required to protect the well-being of the participant.
Screening Period 1 Period 2mEarly 
Termination/
DiscontinuationFollow-upn
Visit Identifiera
Abbreviations used in this table 
may be found in Appendix 8Day -28 to 
Day -2Day -1 Day 1 Day 2 Day 3 Day 1 Day 2 to 
Day 8Day 9 Day 10 Day 11 Day 12 28-35 days after 
last dose
Informed consent X
CRU confinement X →→→→ → → →→ X
Inclusion/exclusion criteria X X
Medical, drug, tobacco and alcohol 
histor yXX
Contraception check X X XX
Pregnancy test (for WOCBP) X X X
Demography X
Physical examinationbXX
Safety laboratory X X X X X
TB ScreencX
Serum FSH (postmenopausal women 
only)X
Serology: Viral screen, HBsAg, 
HCVAb, HIV, HBsAb and HBcAbX
 
Urine drug screen X X
12-Lead ECG (single) X X X X
Vital signs (supine BP, pulse rate)eXX X X X X
COVID-19 questionnairefXX
COVID-19 testinggXX
COVID-19 check temperaturehXX →→→→ → → →→ XXCCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 12Screening Period 1 Period 2mEarly 
Termination/
DiscontinuationFollow-upn
Visit Identifiera
Abbreviations used in this table 
may be found in Appendix 8Day -28 to 
Day -2Day -1 Day 1 Day 2 Day 3 Day 1 Day 2 to 
Day 8Day 9 Day 10 Day 11 Day 12 28-35 days after 
last dose
OC dosingiXX
PF-06650833 QD dosingjXX X X X
OC PK blood samplek,lXXX X X X X
Serious and non-serious AE monitoringX →→→ →→ → →→→ → XX
Prior/concomitant treatment
assessmentX →→→ →→ → →→→ XX X
CRU discharge X
a. Visit Identifier : Day relative to start of study treatment (Day 1).
b. Physical Examination: Complete physical exam could be done at screening or admission on Day -1. Brief physical exam to be done only in case of findin g at previous exam 
or new/open AE if applicable, at the discretion of the investigator.
c. TB Screen: QFT-G test.
 
e. Vital signs (supine BP, pulse rate): Vital signs will be collected before dosing.
f. COVID-19 questionnaire: Check exposure to positive participant, residence or travel in area of high incidence and COVID-19 related signs and symptoms. 
g. COVID-19 testing :The testing for COVID-19 pathogen by PCR will be performed screening and D-1. A subsequent COVID-19 test can be performed if part icipants 
admitted for residence develop COVID-19 like symptom(s).
h. COVID-19 check temperature: To be done twice daily during residence.
i. OC dosing: Participants will be dosed with OC following an overnight fast of at least 10 hours. On the day of co-administration of OC and PF-0 6650833, the two will be 
administered simultaneously within 5 minutes.
j. PF-06650833 QD dosing: The daily dose of PF-06650833 will be administered at approximately 08:00 ±2 hours.
k. OC PK blood sample: PK blood samples are to be collected at predose, at 30 minutes and 1, 1.5, 2, 4, 6, 8, 12, 24, 36 and 48 hours post OC dose in Per iods 1 and 2.
l. OC PK blood sample: The 24 hour OC PK samples on Period 2 Day 11 must be collected pre PF-06650833 dose.
m. Period 2: There is no washout phase between Period 1 and Period 2.
n. Follow-up: Participants will have a telephone contact at least 28 calendar days, and up to 35 calendar days after the last administration of the investigational product(s). At 
the discretion of the investigator, telephone contact may be substituted with an on-site visit in case of additional follow-up of open AEs or clinically significant laboratory 
findingsCCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 132. INTRODUCTION
PF-06650833 is a selective and reversible inhibitor of IRAK4 which is under clinical 
development as a potential treatment for RA, HS, COVID-19 and acne vulgaris.
2.1. Study Rationale 
This study will evaluate the effect of PF-06650833 on pharmacokinetics of OC steroids, in 
order to select appropriate contraception requirements in Phase 2 studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The metabolism of OC steroids such as EE and LN, is mediated by the CYP3A and Phase 2 
enzymes such as UGT and SULT. Induction of the metabolic enzymes involved in 
metabolism of OC’s may result in reduction in the systemic exposure of these hormonal contraceptives leading to a potential failure of contraception. Therefore, the current study is designed to estimate the effect of multiple dose of PF-06650833 on the PK of 2 commonly concomitantly administered OCs, EE and LN.CCI
CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 142.2. Background 
2.2.1. Nonclinical PharmacologyPF-06650833 is a highly selective inhibitor of IRAK4 with nanomolar potency both in 
recombinant enzyme assays and in cellular assays. PF-06650833 inhibits IRAK4 with low nmol/L (IC
50<5 nmol/L) potency in cell based assays of TLR-mediated cytokine induction. 
In the rat CIA model, PF-06650833 dosed orally at 3 to 100 mg/kg BID or 30 and 100 mg/kg QD significantly reduced hind paw swelling.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.4. Clinical Overview
As of the date of this protocol, PF-06650833 has been evaluated in 7 completed Phase 1 
studies (B7921001, B7921002, B7921004, B7921006, B7921011, B7921009 and B7921028) and 1 completed Phase 2 study in RA patients (B7921005) and 3 ongoing Phase 2 studies in patients with RA (B7921023), HS (C2501007) and COVID-19 with ARDS (I-RAMIC).
Study B7921001 and B7921002 were SAD and MAD studies in healthy participants, 
respectively. B7921004 and B7921011 were relative bioavailability studies. B7921009 was a mass balance study while B7921006 was multiple dose PK and safety assessment in Japanese participants. CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 16 
 
 
 
 
 
In all of the completed Phase 1 and Phase 2 studies, PF-06650833 was generally well 
tolerated and no maximally tolerated dose has been established. No deaths or other SAEs occurred in any of the studies. The most commonly observed AEs were headache and AEs within the SOC of ‘GI disorders’ (diarrhoea, abdominal discomfort, abdominal distension, abdominal pain, dry mouth, enterocolitis and flatulence). All TEAEs were mild to moderate 
in severity.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of Clinical PK
In Studies B7921001 and B7921002, PF-06650833 exposure (AUC and C max) increased in a 
dose related manner up to the 100 mg dose, with less-than-proportional increases observed at higher doses. Accumulation ranged from 0.9-fold to 1.4-fold for AUC
tauand 0.9 fold to 
1.3 fold for C max. Less than 1% of the dose was recovered unchanged in urine.CCICCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 17 
 
 
 
 
 
 
 
 
 
 
 
2.3. Benefit/Risk Assessment
PF-06650833 is not expected to provide any clinical benefit to healthy participants. This 
study is designed primarily to generate safety, tolerability, and pharmacokinetic data for further clinical development.
In the clinical studies of PF-06650833 (see Section 2.2.4 ), the investigational product was
determined to be well tolerated and to have an acceptable safety profile. 
 
 
 
 
 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of PF-06650833 may be found in the IB, which is the SRSD for this study.
The expected exposures of PF-06650833 in this study are lower than the highest exposures 
observed in the Phase 1 studies (see Justification for Dose in Section 4.3 ). 
 
herefore, the 
risk to the participants in this study is expected to be minimal. In addition, any risks are minimized by appropriate safety measures including safety laboratory measurements, ECGs, vital signs for study participants.CCI
CCI
CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 182.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s): PF-06650833
 
 
 
  
 
 
 
  
 
 
 
 
 
Other 
The COVID-19 pandemic may pose risks to study participation. Participants may have increased risk of 
SARS-CoV-2 infection by undergoing a study 
procedure at a study facility.Inclusion of COVID-19 specific assessments 
according to the Schedule of Activities and CRU 
confinement for the entire duration of study.CCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 192.3.2. Benefit Assessment
There is no benefit expected to the participants.
2.3.3. Overall Benefit /Risk Conclusion
PF-06650833 is not expected to provide an y clinical benefit to health y participants. Study  in 
healthy  participants is justified by  taking into account the measures to minimize potential 
risk.
3.OBJECT IVES AND ENDPOINTS
Objectives Endpoints
Prim ary: Prim ary: 
To estimate the effect of multiple oral doses of 
PF-06650833 on the PK of a single dose of a 
combination OC in healthy female participan ts.Cmaxand AUC lastof EE and LN .
Secondary: Secondary : 
To evaluate the safety of PF -06650833 when 
co-administered with a single dose of a 
combination OC in healthy female participan ts.Safety: laboratory tests, AEs reporting and vital 
signs.
Tertiary/Exploratory: Tertiary/Exploratory: 
To characterize the PK of a single dose of a 
combination OC with or without PF -06650833
in healthy female participan ts.Tmax, and if data permit CL/F , t½and AUC inf, of 
EE and LN.
4.STUDY DESIGN
4.1.Overall Design
This is a Phase 1, fixed -sequence, multiple -dose, open- label study  of the effect of multiple 
dose PF -06650833 on single dose OC PK in healthy  female participan ts. A total of
approximately  10health y female participants will be enrolled in the study . The study will 
consist of 2 periods in a single fixed sequence. Participants will be screened within 28 days 
of the first dose of investigational product in Period 1. Participants will report to the CRU the 
day prior to Day  1 dosing in Period 1. Participants will remain in the CRU for a total of 
16days and 15 nights. There will be no washout period. 
OnPeriod 1 Day  1, participants will be dosed with a single administration of OC in the form 
of 1 PORTI A®(EE and LN) or equivalent tablet, orally . OC (EE and LN) PK will then be 
assessed at pre -dose and over 48 hours, pos t OC dosing. Period 1 will be immediately  
followed b y Period 2 with no washout, in which participants will be dosed orally  with 
PF-
06650833 400 mg MR QD for 9 day s followed by  administration of a single dose of OC 
on the morning of Day  10. OC PK will be as sessed at pre- dose and for 48 hours following 
OC dosing. On Day  10, the morning dose of PF -06650833 and the single OC dose will be 

PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 20administered simultaneously within 5 minnutes. Dosing with PF-06650833 400 mg PO QD 
will continue until Day 11 (Table 1). Participan ts will be discharged on Day 12 only after 
review of safety laboratory by the PI.
Table 1. Study Design and Treatments
Period 1 Washout Period 2
Treatment A None Treatment B
Treatment A: Single dose of OC in the form of 1 PORTIA®(EE and LN) or equivalent oral tablet, containing 
EE 30 μg and LN 150 μg.
Treatment B: Single dose of combination OC in the form of 1 PORTIA®(EE and LN) or equivalent oral 
tablet, containing of EE 30 μg and LN 150 μg on the morning of Day 10 fo llowing 9 days of PF-06650833 
dosed at 400 mg PO QD. Dosing with PF-06650833 at 400 mg PO QD will continue through until Day 11.
4.2. Scientific Rationale for Study Design
Given the potential teratogenicity risk of PF-06650833 and potential of CYP3A induction 
risk, only WONCBP will be allowed in this study.
A fixed sequence design was selected for this study over a randomized 2-sequence crossover 
design based on operational considerations. It should be noted that the fixed sequence study design does not control for a period effect, however, the period effect is generally considered to be a low risk for PK DDI studies.
Based on the in vitro metabolic profiling, there is low potential of oral contraceptive steroids 
to impact PK of PF-06650833, only the effect of PF-06650833 will be evaluated in this study. In order to allow the full effect of potential enzyme induction of CYP3A4 to manifest, PF-06650833 will be dosed for 10 days prior to OC dosing. This is supported by Simcyp simulations showing maximal induction of CYP3A4 by PF-06650833 under the study design.
Due to the effect of food on PK of PF-06650833 MR and consistent with Phase 2 studies, 
PF-06650833 will be dosed in fasted state in this study. 
4.2.1. Diversity of Study Population
Not applicable.
4.2.2. Choice of Contraception/Barrier Requirements 
 
herefore, the use of a highly effective method 
of contraception is required (see Appendix 4 ).
 
CCICCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 214.3. Justification for Dose
The current study will use a PF-06650833 dose of 400 mg MR QD. This is the highest dose 
of PF-06650833 planned for use in future efficacy and safety trials. 
PF-06650833 was well tolerated in doses up to 1000 mg QID for up to 14 days in healthy 
participants without dose-limiting adverse effects being demonstrated when administered as an orally- administered extemporaneously-prepared IR formulation (Study B7921002). 
 
 
 
 
The dose of combination OC is determined in part by the choice of commercially available 
products and recent precedents at Pfizer in the conduct of OC DDI studies. PORTIA
®
(EE and LN) or equivalent containing 30 μg of EE and 150 μg of LN will be used in this 
study. OC will be administered as a single dose with and without PF-06650833. 
4.4. End of Study Definition
The end of the study is defined as the date of last scheduled procedure shown in the SoA for 
the last participant in the trial.
A participant is considered to have completed the study if he/she has completed all periods of 
the study, including the last visit as shown in the SoA.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled. The 
following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.CCI
CCICCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 225.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1.Health y female participan tswho, at the time of screening, are between the ages of 
18and 60 years, inclusive. Health y is defined as no clinically relevant abnormalities 
identified by  a detailed medical history , full phy sical examination, including BP and 
pulse rate measurement, 12- lead ECG, or clinical laboratory  tests.
2.Female participan tsof non -childb earing potential must meet at least 1 of the 
following criteria:
a.Achieved postmenopausal status, defined as follows: cessation of regular menses 
for at least 12 consecutive months with no alternative pathological or 
physiological cause; and have a serum FSH level confirming the postmenopausal 
state;
b.Have undergone a documented hy sterectomy  and/or bilateral oophorectomy
and/or 
bilateral salpingectomy ;
c.Have medically  confirmed ovarian failure .
All other female participan ts(including female participan tswith tubal ligations) are 
considered to be of childbearing potential. Refer to Appendix 4 :Contraceptive and 
Barrier Guidance forreproductive criteria for female ( Section 10.4.2) participants.
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
Weight:
4.BMI of 17.5 to 30.5 kg/m2; and a total body  weight >50 kg (110 lb).
Informed Consent:
5.
Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the I CDand in 
this protocol.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 235.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing) .
2.Any condition possibly  affecting drug absorption (eg, gastrectomy , cholecy stectom y).
3.Infection with hepatitis B or hepatitis C viruses according to protocol -specific testing 
algorithm.
For hepatitis B, all participants will undergo testing for HB sAg and HBcAb 
during Screening. Participants who are HBsAg positive will not be eligible for 
this study . Participants who are HBsAg negative but HBcAb positive will be 
reflex -tested for HBsAb. Please refer to Sectio n 10.2 for testing algorithm, reflex 
testing, and full eligibility  criteria.
For hepatitis C, all participants will undergo testing for HCVAb during Screening. 
Participants who are HCVAb positive will be reflex tested for HCV RNA. 
Participants who are HCVA b and HCV RNA positive are not eligible for the 
study . Participants who are HCVAb positive but HCV RNA negative will be 
considered eligible.
4.Have evidence of untreated or inadequatel y treated active or latent M ycobacterium 
TB infection as evidenced by  the following:
A positive QFT -G test performed at screening . Ifthe laboratory  reports the test as 
indeterminate, the test should be repeated. If the result of the repeat test is 
indeterminate, a PPD test may  be substituted for the QFT -G test onl y with 
approval from the Pfizer Medical Monitor on a case by  case basis.
History  of either untreated or inadequately treated latent or active TB infection.
If a participant has previously  received an adequate course of therap y for 
either latent (9 months of isoniazid in a locale where rates of primary  multi 
drug resistant TB infections are <5% or an acceptable alternative regimen) or 
active (acceptable multi -drug regimen) TB infection, nether a QFT -G test not 
a PPD test need to be obtained. Details of previous cou rse of therap y 
(eg,medication(s) used, dose, duration of therapy) should be documented in 
the source documentation.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 24A participant who is currently  being treated for active or latent TB infection 
must be excluded from the study .
5.Participants with any  of th e following acute or chronic infections or infection history :
Any infection requiring treatment within 2 weeks prior to the screening visit.
Any infection requiring hospitalization, parenteral antimicrobial therapy  within 60 
days of the first dose of inves tigational product.
Any infection judged to be an opportunistic infection or clinically  significant by  
the investigator, within the past 6 months of the first dose of the investigational 
product.
Known active or history  of recurrent bacterial, viral, funga l, my cobacterial or 
other infections.
History  of a recurrent (more than one episode of) localized, dermatomal herpes 
zoster, or history  of disseminated (one single episode) herpes simplex or 
disseminated herpes zoster.
6.History  of febrile illness within 5 days prior to the first dose of investigational 
product.
7.History  of any  lymphoproliferative disorder such as EBV related l ymphoproliferative 
disorder, history  of lymphoma, history  of leukemia, or signs and s ymptoms 
suggestive of current ly mphatic or ly mpho id disease.
8.Participants have a known present or a history  of malignancy  other than a 
successfull y treated or excised non metastatic basal cell or squamous cell cancer of 
the skin or cervical carcinoma in situ.
9.Benign ethnic (cy clic) neutropenia.
10.Having re ceived an y live (attenuated) vaccines, except COVID -19 vaccines within 
6 weeks prior to the first dose of investigational product.
11.Have received COVID -19 vaccine within 14 day s before first dose of study 
intervention or have received only  one of the 2 requ ired doses of COVID -19 vaccine.
12.Cardiovascular risk factors including but not limited to my ocardial injury , venous 
thromboembolism, and pulmonary  embolism.
13.Pregnant female participants
; breastfeeding female participants.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 2514.Other medical or psy chiatric condit ions including recent (within the past y ear) or 
active suicidal ideation /behavior or laboratory  abnormality  or other conditions or 
situations related to COVID -19 pandemic (eg ,Contact with positive case, residence, 
or travel to an area with high incidence) that may  increase the risk 
ofstudy 
participation or , in the investigator’s judgment, make the participant inappropriate for 
thestudy .
Prior/Concomitant Therapy:
15.Use of prescription or nonprescription drugs and dietary  and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention . (Refer to Section 6.8 Concomitant Therap y for additional details).
Prior/Concurrent Clinical Study Experience:
16.Previous administr ation with an investigational drug within 30 days (or as determined 
by the local requirement) or 5 half-lives preceding the first dose of study  intervention
used in this study  (whichever is longer). 
Diagnostic Assessments:
17.A positive urine drug test .
18.Screening supine BP ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least 5 minutes of supine rest. If BP is ≥140 mmHg (s ystolic) or ≥90mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility .
19.Baseline standard 12- lead ECG thatdemonstrates clinically relevant abnormalities that 
may affect participant safety or interpretation of study results (eg, baseline QTc F
interval >450 msec, complete LBBB, signs of an acute or indeterminate- age 
myocardial infarction, ST -T interval changes suggestive of my ocardial ischemia, 
second -or third -degree AVblock, or serious brady arrhy thmias or tachy arrhy thmias). 
If the baseline uncorrected QT interval is >450 msec, this interval should be 
rate-corrected using the Fridericia method and the resulting QTcF should be used for 
decision making and reporting. If QTc Fexceeds 450 msec, or QRS exceeds 
120msec, the ECG should be repeated 2 more times and the average of the 3 QTcFor 
QRS values should be used to determine the participant’s eligibility . 
Computer -interpreted ECGs should be overread b y a physician experienced in 
reading ECGs before excluding a participant.
20. Participants with ANY of the following abnormalities in c linical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary : 
AST or ALT level ≥1.5 × ULN;

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 26Total bilirubin level ≥1.5 × ULN; participants with a history  of Gilbert ’s 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is≤ ULN.
eGFR ≤90 mL /min/1.73m2 based on CKD -EPI equation .
In the opinion of the investigator (or designee), have an y clinicall y significa nt 
laboratory  abnormality  that could affect interpretation of study  data or the 
participant ’s participation in the study .
Other Exclusions:
21.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of 
Screening. Binge drinking is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drinks in about 2 hours . As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit=
8ounces (240 mL) beer, 
1ounce (30 mL) of 40% spirit or 3ounces (90 mL) of wine).
22.Blood donation (excluding plasma donations) of approximately  1pint (500 mL) or 
more within 60 days prior to dosing .
23.History  of sensitivity  to heparin or heparin -induced thrombocy topenia .
24.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol
.
25.Investigator site staff or Pfizer employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised by  the investigator, and their respective family  
members .
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 10 hours prior to the collection of the predose 
PK sample.
Water is permitted until 1 hour prior to study  intervention administration. Water may  
be consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks 
(except grapefruit or grapefruit- related citrus fruit juices—see below) may  be 
consumed with meals and the evening snack.
Lunch will be provided approximately  4 hours after dosing.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 27Dinner will be provided approximately  9to 10 hours a fter dosing.
An evening snack may  be permitted.
Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to the first 
dose of study  intervention until collection of the final PK blood sample.  
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein. The dail y caloric intake 
per participant should not exceed appr oximately  3200 kcal.
5.3.2. Caffeine, Alcohol, and Tobacco
Participant s will abstain from caffeine -
containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study  period.  
Participant s will abstain from alcohol for 24 hours prior (or as specified above for red 
wine) to admission to the CRU and continue abstaining from alcohol until collection 
of the final PK sample of each stud y period. Participant s may  undergo an alcohol 
breath test or blood alcohol test at the discretion of the investigator.
Participan tswill abstain from the use of tobacco -or nicotine -containing products for 
7 day s prior to dosing, during confinement in the CRU and between P eriods 1 and 2.
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav
y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted.
In order to standardize the conditions on PK sampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and 
ECG measurements), eating, and drinking beverages other than water during the first 
4
hours after dosing.
5.3.4. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contrac eption methods (see 
Appendix 4 Section 10.4.4 ) and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the SoA , the investigator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant’s affirmation in the 
participant’s 
chart (participants need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception) considering that their risk for pregnancy  may  have changed since 

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 28the last visit. I n addition, the investigator or desi gnee will instruct the participant to call 
immediately  if the selected contraception method is discontinued or if pregnancy  is known or 
suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to part icipate in the clinical study but 
are not subsequently  enrolled to study  sequences. Screen failure data are collected and 
remain as source and are not reported on the CRF .
Individuals who do not meet the criteria for participation in this study  (screen fai lure) may  be 
rescreened. Only  one rescreening will be permitted per participant.
6. STUDY INTERVENTION(S) AND CO NCOMITANT THERA PY
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
For the purposes of this protocol, the term investigational product may  be used 
synony mously  with study  intervention.
6.1.Study Intervention(s) Administered
For the purposes of this protocol, study  intervention refers to PF -06650833.
PORTI A®(or equivalent) is a nNIMP.
PF-
06650833 200- mg MR tablets will be provided by  Pfizer to the CRU in bulk along with 
individual dosing containers and desiccants for unit dosing.
Study  intervention will be presented to the participant s in individual dosing containers.
PORTI A®(or equivalent)
will be supplied by  the CRU .All PORTIA®or equivalent oral 
tablet used in this study  should be from the same manufacturing batch.
6.1.1. Administration
Following an overnight fast of at least 10 hours , participants will receive one PORTIA®or 
equivalent tablet on Period 1 Day 1at approximately  08:00 hours (plus or minus 2 hours). On 
the day s of co -administration ofOCand PF- 06650833 (Period 2 Day  10), one PORTIA®or
equivalent tablet should be administered simultaneously  within 5 minutes of two 200- mg 
PF-
06650833 MR tablets dosing. Investigator site personnel will administer investigational 
product during each period with ambient temperature water to a total volume of 
approximately  240 mL. Additional water is allowed if needed to complete administration of 
the entire dose. Participants will swallow the investigational product whole, and will not 
manipulate or chew the investigational product prior to swallowing.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 29In order to standardize the conditions on PK sampling day s, all participants will be required 
to refrain fro m lying down (except when required for BP, pulse rate, and ECG 
measurements), eating, and drinking beverages other than water 4 hours after dosing.
6.1.2. Medical Devices
Not applicable .
6.2.Preparation , Handling , Storage , and Accountability
1.The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study may receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance wit h the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon return to business
.
3.Any excursions from the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along wit h any actions taken. The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until Pfizer provides permission 
to use the study  intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the I P manual.
4.Any storage conditions s tated in the SRSD will be superseded b y the storage 
conditions stated on the label.
5.Study  interventions should be stored in their original containers.
6.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible f or study  intervention accountability , reconciliation, and record 
maintenance (e g, receipt, reconciliation, and final disposition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 307.Further guidance and information for the final disposition of unused study  
interventions are provided in the I P manual. All destruction must be adequately  
documented. If destruction is authorized to take place at the invest igator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y Pfizer.
Upon identification of a product complaint, notify th e sponsor w ithin 1 business day  of 
discovery  as described in the I P manual.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by qualified 
staff. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  qualified staff member(s) to a healthcare provider, 
partici pant in accordance with this protocol. L ocal health authority  regulations or investigator 
site guidelines may  use alternative terms for these activities.
Tablets will be prepared at the CRU in the individual dosing containers b y 2operators, 1 of 
whom is a n appropriatel y qualified and experienced member of the stud y staff (eg, ph ysician, 
nurse, ph ysician’s assistant, nurse practitioner, pharmacy  assistant/technician, or pharmacist). 
The tablets will be provided in unit dose containers and labeled in accorda nce with Pfizer 
regulations and the clinical site’s labeling requirements. 
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participant s are enrolled.
The investigator will assign participant numbers to the 
participant s as they  are screened for 
the study .
6.3.2. Breaking the Blind
Not applicable.
6.4. Study Intervention Compliance
Investigational product will be administered under the supervision of investigator site 
personnel. The oral cavity of each participant will be examined following dosing to ensure 
the investigational product was taken.
6.5. Dose Modification
Not applicable .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 316.6.Continued Access to Study Intervention A fter the End of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -06650833 greater than 6 g within a 24 -hour time period will 
be considered an overdose.
There is no specific treatment for an overdose with PF -06650833.
In the event of an overdose, the investigator should:
1.Contact the medical monitor within 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of study  investigational 
products (whichever is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Pfizer Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within 7 day s from the date of the last dose of 
study  intervention(s) if requested by  the medical monitor (determined on a 
case-by-case basis).
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant .
6.8.Concomitant Therapy
Use of prescription or nonprescription drugs and die tary and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed to affect 
participant safety  or the overall resul ts of the study may  be permitted on a case -by-case basis 
following approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses of 
≤
1g/day .
Females using hormone replacement therap y ma y be eligible to participate in this study  if 
they are willi ng to discontinue therapy  at least 28 days prior to the first dose of study  
treatment and remain off hormonal therap y for the duration of the study.
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start a nd stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 32Treatments taken within 28 days before the first dose of study  intervention will be 
documented as a prior treatment. Treatments taken aft er the first dose of study  intervention 
will be documented as concomitant treatments.
6.8.1. Rescue Medicine 
There is no rescue therapy to reverse the AEs observed with PF-06650833 or OC ; standard 
medical supportive care must be provided to manage the AEs. 
7.
DISCONTINUATION OF STUD Y INTERVENTION AND P ARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention. Reasons 
for permanent discontinuation of study  interven tion include the following: liver injury , ECG 
changes, acute kidney  injury , pregnancy ,or laboratory  abnormalities. Please refer to 
subsections 
7.1.1 through 7.1.5 for details of each. 
If study  intervention sarepermanentl y discontinued, the participant will not remain in the 
study  for further evaluation. See the SoA for data to be collected at the time of 
discontinuation of study  intervention s.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y interventions or also from study  procedures, posttreatment study  follow-up, 
and/or future collection of additional information.
7.1.1. Liver Injury
All of the following laboratory  abnormalities require discontinuation if they  are confirmed:
AST or ALT that meet ANY of the following:
>3 × ULN with at least one total bilirubin val ue >2 × ULN .
>3 × ULN accompanied by  signs or symptoms consistent with hepatic injury  (eg, new 
onset elevated PT/INR) .
Two sequential AST or AL T elevations >5 × ULN, regardless of total bilirubin or 
accompan ying signs or sy mptoms.
7.1.2. ECG Changes
A participant who meets either bulleted criteria based on the average of triplicate ECG 
readings will be withdrawn from the stud y interventions. 
QTcF >500 msec.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 33Change from baseline: QTcF >60 msec and QTcF >450 msec.
If a clinically  significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if 
the participant can continue in the study  and if any change in parti cipant management is 
needed. This review of the ECG printed at the time of collection must be documented. An y 
new clinicall y relevant finding should be reported as an AE.
7.1.3. Potential Cases of Acute Kidney Injury
Abnormal values in SCr concurrent with presenc e or absence of increase in BUN that meet 
the criteria below, in the absence of other causes of kidney  injury , are considered potential 
cases of acute kidney  injury  and should be considered important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5 µ mol/L) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr as soon as practicall y 
feasible, preferabl y within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [or ≥ 26.5 µ mol/L ]in SCr
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 µ mol/L ), the 
participant should be discontinued from the stud y and adequate, immediate, supportive 
measures taken to correct apparent acute kidney  injury .
Participants should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the second assessment confirming abnormal 
SCr result. This evaluation should include laboratory  tests, detailed hi story , and phy sical 
assessment. In addition to repeating SCr, laboratory tests should include serum BUN, serum 
creatine kinase, and serum electrol ytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary  dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 
laboratory  criteria for acute kidney  injury , with no other cause(s) of laboratory  abnormalities 
identified, should be considered potential cases of drug- induced kidney  injury  irrespective of 
availability  of all the results of the investigations performed to determine etiology  of the 
abnormal SCr. If ≥2healthy  participants in a given period are noted to have 2 consecutive
SCr results of ≥0.3 mg/dL (or ≥26.5 µ mol/L ), an assessment of whether the finding may  be 
considered an adverse drug reaction should be undertaken.
7.1.4. Pregnancy
In the case of a positive serum pregnancy  test, the participant will have investigational 
product stopped and resul t re-confirmed via a second urine test or serum sample collected on 
the same day  (or as soon as possible) and submitted to the laboratory  for pregnancy  testing.
7.1.5. Laboratory Abnormalities
All of the following laboratory  abnormalities require discontinuation if they are confirmed:
ANC <750/mm3(<0.75 × 109/L).

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 34Hemoglobin <9.0 g/dL (<5.59 mmol/L  or <90 g/L) or a decrease of >30% from 
baseline (either criterion or both) .
Platelet count <75,000/mm3(<75.0 × 109/L).
ALC <500/mm3(<0.5 × 109/L).
NOTE: Participants with AL C <500/mm3(0.5 × 109/L) will be reflex tested for 
FACS -TBNK until the absolute ly mphocy te count resolves or stabilizes at a level 
acceptable to the investigator and sponsor.
CK >10 × ULN .
NOTE: Urine m yoglobin and SCr will be per formed as reflex testing for any  participant 
with CK >10 × ULN
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further study  procedures ;
Lost to follow -up;
Death ;
Study  terminated by  sponsor ;
At the discretion of the investigator for safet y, behavioral, compliance, or 
administrative reasons
.
At the time of discontinuing from the stud y, if possibl e, an earl y discontinuation visit should 
be conducted . See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  discontinuati onvisit applies only  to participants who are enrolled and then are 
prematurel y withdrawn from the study. Participants should be questioned regarding their 
reason for withdrawal. 
The participant will be permanentl y discontinued from the study intervention s and the study  
at that time.
If a participant withdraws from the study , he/she may  request destruction of any  remaining
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor acc ordingly .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 35If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected befo re such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with him or her or persons previously  authorized by  the participant to provide this 
information. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedur es and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Fol lowup 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to attend a required study  visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study .
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record .
Should the participant continu e to be unreachable, he/she will be considered to have 
withdrawn from the study. 

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 368.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specifi c procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure , as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 28 days as a result of u
nexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
A participant who qualified for this protocol but did not enroll fro m an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility  criteria for this study . In 
addition, other clinical assessments or specime n collections, eg, banked biospecimens, may  
be used without repeat collection, as appropriate.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time t here may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -requir ed test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 37The total blood sampling volume for individual participant s in this study  is approximate ly 
350mL. The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times specified b y Pfizer, provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 
56consecutive 
days.
To prepare for stud y participation, participant s will be instructed on the information in the 
Lifesty le Considerations and Concomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
Not applicable .
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart a nd lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respiratory  and cardiovascular s ystems, and 
participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Physical examination findings collected during the study  will be considered source da ta and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3) must be reported according to the processes in 
Sections 8.3.1 to8.3.3.
8.2.2. Vital Signs
Supine BP will be measured with the participant’s arm supported at the level of the heart, and 
recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm 
(preferabl y the dominant arm) will be used throughout the study . Participants should be 
instructed not to speak during measurements.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 38The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery for at least 
30seconds. When the timing of the se measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection. 
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary , to ensure appropriate collection of safety  data .
8.2.3. Electrocardiograms
Standard 12-l ead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex . Alternative lead placement methodology using torso leads (eg, Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs a cquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant
has rested quietl y for at least 5 minutes in a supine position. 
To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased by  ≥60 msecfrom the baseline andis >450 msec ; or b) 
an absolute QT value is ≥500 msecfor an y scheduled ECG.  If either of these conditions 
occurs, then 2 additional ECGs will be collected approximately  2to 4minutes apart to 
confirm the original measurement. If the QTc values from these repeated ECGs remain above 
the threshold value, then a single ECG must be repeated at least hourl y until QTc values from 
2successive ECGs fall below the threshold value that triggered the repeat measurement.
If a) a postdose QTc Finterval remains ≥60msecfrom the baseline andis >450 msec; or 
b)an absolute QT value is ≥500 msecfor an y scheduled ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator) ;or c) QTcFintervals get progressively longer, 
the participant should undergo continuous ECG monitoring. A cardiologist should be 
consulted if QTc Finterval s do not return to less than the criteri alisted above after 8 hours of 
monitoring (or sooner, at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality . It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical pr ovider’s interpretation determines that the QTc Fvalues are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 398.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the SoA for 
the timing and frequency. All protocol -required laboratory  assessments, as defined in 
Appendix 2 , must be conducted in accordance with the laboratory  manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues
.  
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 
28 calendar days after the last dose of study  intervention 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator, the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -up assessments in the event of potential 
drug-induced liver injury.
Participant s may  undergo random urine drug testing at the discretion of the investigator. 
Drug testing conducted prior to dosing must be negative for participant s to receive study  
intervention . 
8.2.5. COVID -19 S pecific Assessments
Participants will be tested for SARS -COVID -19 infection by  PCR prior to being admitted to 
the clinic for confinement andif they  develop COVID -
19 like s ymptoms. Additional testing 
may be required by  local regulations or by  thePI.
8.2.6. Pregnancy Test ing
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA . 
Following a negative pregnancy  test result at screening, a ppropriate contraception must be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant’s receiving the stud y intervention. Pregnancy tests will also be done 
whenever 1 menstrual cycle is missed d uring the active treatment period (or when potential 
pregnancy  is otherwise suspected) and at the end of the study . Pregnancy  tests may  also be 
repeated if requested b y IRBs/ECs or if required by local regulations. If a urine test cannot be 
confirmed as ne gative (eg, an ambiguous result), a serum pregnancy  test is required. In such 
cases, the participant must be excluded if the serum pregnancy  result is positive.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 408.3.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE andanSAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  the 
participant (or, when appropriate, b y a caregiver, or surrogate), or they  may  arise from 
clinical findings of the Investigator or other healthcare providers (clinical signs, test results, 
etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE
and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
thestudy  (see Section 7.1 ). 
During the active collection period as described in Section 8.3.1, e ach participant/legal 
guardian/legall y authorized representative will be questioned about the occurrence of AEs in 
a nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained befor e the participant ’s participation in the study  (eg, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of 28 calendar days ,after the last administration of the study  intervention .
Follow -up by  the investigator continues throughout and after the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study
 and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporaril y discontinues study intervention
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek information on AEsor SAE safter th e 
participant has concluded study  participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the study , and he/she 

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 41considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to Pfizer using the CT SAE Report Form.
8.3.1.1.
Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during t he active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety on the CT SAE Report Form imme diately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs repo
rted by  the participant.
Reporting of AEs and SAEs for participants who fail screening are subject to the CRF 
requirements as described in Section 5.4 .
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at su bsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appendix 3.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 428.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulato ry authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSARs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact with or exposure to the study intervention. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study  intervention under study  are reportable to Pfizer Safet y 
within 24 hours of investigator awareness.
8.3.5.1. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention.
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP:
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  ingestion.
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anti cipated date of delivery (see below for information related to 
termination of pregnancy). 

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 43If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety on the CT SAE Report Form and an EDP 
Supple mental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until after the start 
of study  interventions and until a minimum of 28 calendar day s after last dose .
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrit y of t he neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (u nless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (e g, ectopic pregnancy , spontaneous abor tion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information abo ut pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addit ion, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  the sponsor. Fur ther 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 448.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if:
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention.
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (e g, environmenta l exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by ingestion.  
The investigator must report e xposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the sett ing of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study, so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding
.
8.3.5.3. Occupational Exposure
The investigator must report any  instance of occupational exposure to Pfizer Safet y within 
24
hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether there is an associated SAE. Since the information about the occupational exposure 
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of the c ompleted CT SAE Report Form must be maintained in the 
investigator site file .
8.3.6.
Cardiovascular and Death Events
Not applicable .
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable .
8.3.8. Adverse Events of Special Interest
Not applicable .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 458.3.8.1. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not applicable .
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by the wrong participant , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors o ccurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE page of the 
CRF.
Medication errors should be reported to Pfizer Safety  within 24 hours on a CT SAE Report 
Form only when associated with an SAE.

PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 468.4. Pharmacokinetics 
Plasma for analysis of EE and LN
Blood samples of approximately 6 mL (2 × 6 = 12 mL), to provide approximately 2.5 mL 
plasma for each EE and LN will be collected into appropriately labeled tubes containing K
2EDTA for measurement of plasma concentrations of EE and LN as specified in the SoA. 
Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by the sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the CRF. Collection of samples more than 10 hours after doseadministration that are obtained ≤1 hour away from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the CRF. This protocol deviation window does not apply to samples to be collected more than 10 hours after dose administration at outpatient/follow-up visits with visit windows.
Samples will be used to evaluate the PK of OC steroids (EE and LN). Samples collected for 
analyses of OC steroids (EE and LN) concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method,  
 
Samples collected for measurement of plasma concentrations of OC steroids (EE and LN)
will be analyzed using a validated analytical method in compliance with applicable SOPs.
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shipping 
conditions), including any actions taken, must be documented and reported to the sponsor.  On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.CCI
CCI
CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 47 
 
 
 
8.7. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in an SAP, which will be maintained by the sponsor. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
No formal inferential statistics will be applied to the safety or PK data.CCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 489.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Population Description
Enrolled All participants who sign the I CD. A participant will be 
considered enrolled if the informed consent is not withdrawn 
prior to participating in any  study  activity  after screening.
Assigned to
investigational productAll participants who sign the I CD and meet all eligibility  
criteria.
Evaluable All participants enrolled to investigational product and who
take at least 1 dose of investigational product. 
Safety All participants enrolled to investigational product and who 
take at least 1 dose of investigational product.
9.3. Statistical Anal yses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary and secondary  
endpoints.
9.3.1. Pharmacokinetic Analyses
The PK concentration population is defined as all participants that received at least 1 dose of 
investigational product and have at least 1 plasma concentration value reported in at least 
1period. The PK parameter anal ysis population is defined as all participants that received at 
least 1 dose of investigational product and have at least 1 of the PK parameters of primary  
interest reported in at least 1 period.
PK parameters for EE and L N following alone an d co-administration with PF -06650833 will 
be derived from the concentration
-time profiles using non- compartmental methods as data 
permit. The PK parameters to be assessed in this study , their definition, and method of 
determination are outlined in Table 2. In all cases, actual PK sampling times will be used in 
the derivation of PK parameters .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 49Table 2. Plasma Pharmacokinetic Parameter Definitions
Param eter Definition Method of Determ ination
Cmax Maximum plasma concentration 
during the dosing intervalObserved directly from data
Tmax Time for C max Observed directly from data as time of first occurrence
AUC last Area under the plasma 
concentration -time profile from 
time 0 to the time of the last 
quantifiable concentration (C last)Linear/Log trapezoidal method
AUC infaArea under t he plasma 
concentration -time profile from 
time 0 extrapolated to infinite 
timeAUC last+ (C last/kel),
where C lastis the predicted plasma concentration at the 
lastquantifiable time point estimated from the log -linear 
regression analysis
CL/FaApparent clearance Dose/AUC tau
PTR Peak -to-trough ratio Cmax/Cmin
t½aTerm inal elimination half -life Log e(2)/k el,
where k elis the terminal phase rate constant calculated by 
alinear regression of the log -linear concentration -time 
curve. Only those data points judged to describe the 
terminal log -linear decline will be used in the regression
a.If data permit
The plasma PK parameters in Table 2will be summarized descriptivel y by treatment, as 
applicable, in accordance with Pfizer data standards. AUC lastand C maxfor EE and LN
individual participant parameters will be plotted by  treatment. Plasma concentrations will be 
listed and summarized desc riptively  by nominal PK sampling time and treatment. I ndividual 
participant and median profiles of the plasma concentration -time data will be plotted by  
treatment using actual and nominal times respectively. Median profiles will be presented on 
both linear -linear and log -linear scales.
To assess an y effect of PF-06650833 on EE or LN exposures, natural log transformed 
AUC lastand C maxwill be anal yzed using a mixed effects model with treatment as a fixed 
effect and participant as a random effect. Estimates of the adjusted mean differences 
(Test -Reference) and corresponding 90% CIs will be obtained from the model and will be 
exponentiat ed to provide estimates of the ratio of adjusted geometric means (Test/Reference) 
and 90% CIs for the ratios.
The following assessment should be performed:
Effect of PF -06650833 on OC ( EE or LN )exposures with OC alone (Period 1 Day 1
PK) as the Reference treatment and co
-administration of PF -06650833 and OC 
(Period 2 Day 10PK) as the Test treatment.
9.3.2. Safety Analyses
All safet y anal yses will be performed on the s afety population.

PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 50AEs, ECGs, BP, pulse rate, continuous cardiac monitoring, and safety laboratory data will be 
reviewed and summarized on an ongoing basis during the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and physical examination and neurological examination information, as 
applicable, collected during the course of the study will be considered source data and will not be required to be reported, unless otherwise noted. However, any untoward findings identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported.
9.3.2.1. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR 
interval, and QRS complex will be summarized by treatment and time.
The number (%) of participants with maximum postdose QTc values and maximum increases 
from baseline in the following categories will be tabulated by treatment (Table 3): 
Table 3. Safety QTc Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (msec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
In addition, an attempt will be made to explore and characterize the relationship between 
plasma concentration and QT interval length using a PK/PD modeling approach. If a PK/PD relationship is found, the impact of participant factors (covariates) on the relationship will be examined.
 
9.4. Interim Analyses
No formal interim analysis will be conducted for this study. As this is an open-label study,
the sponsor may conduct unblinded reviews of the data during the course of the study for the purpose of safety assessment, facilitating PK/PD modeling, and/or supporting clinical development. CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 519.5. Sample Size Determination
Approximately 10 participants will be enrolled and dosed to achieve at least 8 participants
completing the study.
Table 4
and Table 5 presents the reference boundaries and width of the confidence intervals for a 
range of different estimated effects (estimates of the ratio for pairs of treatments: Test vs Reference).
 
 
 CCI
CCI
PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 52 
 CCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 5310. S UPPORTING DOCUMENT ATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  the spon sor,submitted to an I RB/EC 
by the investigator, and reviewed and approved by  the IRB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for change s necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures
;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (e g, clinical hold) by  an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influen ce the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immediately .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 54In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study partici pants against an y immediate hazard, and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Not applicable .
10.1.3. Informed Consent Process
The investigator or his/her representative w ill explain the nature of the study , including the 
risks and benefits, to the participant or his/her legally  authorized representative and answer 
all questions regarding the study . The participant or his/her legall y authorized representative 
should be give n sufficient time and opportunity  to ask questions and to decide whether or not 
to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that mee ts the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study , and possible risks 
associated with participation, including the risks associated with the pro cessing of the 
participant’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participa nt.
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor, by  
appropriate IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .
A cop y of the ICD(s) must be provided to the participant.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 55Participants who are rescreened are required to sign a new ICD.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password- protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  law.
To protect the rights and freedoms of 
participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant-specific code. The study  site will 
maintain a confidential list of participant s who participated in the st udy, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Committees Structure
10.1.5.1. Data Monitoring Committee 
The study  will not use a DMC .
10.1.6. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulati ons pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 56www.clinicaltrial s.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  US law.
EudraCT
Pfizer posts clinical trial r esults on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the corresponding study  results are
posted to 
www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centrali zed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via
the centralized procedure since 
01 July  2015.
Data sharing
Pfizer provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. Pfizer will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provi ded to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 5710.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
Guidance on completion of CRFs wil l be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t isimportant that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study  critical data items and 
processes (eg, risk- based initiatives in operations and quality , such as risk management and 
mitigation strategies and anal ytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of no ncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and IQMP 
maintained and utilized by  the sponsor or designee.
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 years after study  completion unless local regulations or 
institutional pol icies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y without written notification to the sponsor. The 
invest igator must ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medi cal records. The investigator will promptly  

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 58provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to revi ew and comment on responses to an y such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data report ed on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the Source 
Document Locator.
Description of the use of the computerized system is documented in the Data Management 
Plan, which i s maintained by  the sponsor.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other stud y 
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the da te of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  the responsible I RB/EC or if such termination is 
required to protect the health of study  participants .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 59Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspensio n, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.10. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees t o refer to the primary  publication in any  subsequent publications ,
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide c omments, and the investigator will, on request, remove an y previously undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer -intervention 
related information necessary  for the appropriate scientific presentation or understa nding of 
the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Edi tors.
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites. In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  i
n their entirety and not as 
individual site data. In this case, a coordinating investigator will be designated by  mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with I nternation al Committee of Medical Journal Editors authorship 
requirements. 

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 60If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately  qualified medical personnel for the 
study  is documented in the study  contact list located in theCTMS .
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an Emergency  Contact Card (ECC) at 
the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , 7 day s per week, and (d) Pfizer Call C enter number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  healthcare 
professio nals not involved in the research stud y only , as a means of reaching the investigator 
or site staff related to the care of a participant. The Pfizer Call Center number should only  be 
used when the investigator and site staff cannot be reached. The Pfizer C all Center number is 
not intended for use b y the participant directly ; if a participant calls that number directl y, he 
or she will be directed back to the investigator site.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 6110.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests ( Table 6) will be performed at times defined in the SoA
section of this protocol. Additional laboratory  results may  be reported on these samples as a 
result of the method of analy sis or the t ype of analy zer used by  the clinical laboratory , or as 
derived from calculated values. These additional tests would not require additional collection 
of blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during 
the study  to assess any  perceived safety  issues.
At screening, H BsAg and H BcAb will be tested:
a.If both tests are negative, the participa nt is eligible for study  inclusion;
b.If HBsAg is positive, the participant must be excluded from participation in the study ;
c.If HBsAg is negative and H BcAb is positive, H B
sAb reflex testing is required:
i.If HBsAb is negative, the participant must be excluded from participation in the 
study ;
ii.If HBsAb is positive, the participant is eligible for study
 inclusion.
See Section 8.2.4 for more information on participant safet y monitoring and discontinuation
regar ding clinical lab tests .

PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 62Table 6. Protocol Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
HematocritRBC count
MCV
MCHMCHCPlatelet countWBC countTotal neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)BUN/urea and creatinine
Glucose (fasting)Calcium
Sodium
PotassiumChlorideTotal CO
2(bicarbonate)
AST, ALTTBili
Alkaline phosphatase
Uric acidAlbuminTotal proteinCKpH
Glucose (qual)Protein (qual)
Blood (qual)
KetonesNitritesLeukocyte esteraseUrobilinogenUrine bilirubin
Microscopy
a•Urine drug screeningb
•eGFR
•Viral Screens: CMV, 
EBV, HSV 1&2, VZV
•Pregnancy test ( β-hCG)c
At screening only:
•FSHd
•HBsAg/HBcAb/HBsAb
•HCVAbe
•HIV
•QFT-G Test IGRA
•COVID-19 PCR test
a. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
b. The minimum requirement for drug screening includes cocaine, THC, opiates/opioids, benzodiazepines, 
and amphetamines (others are site and study specific).
c. Local serum testing will be standard for the protocol. Serum or urine β-hCG for female participants of 
childbearing potential.
d. For confirmation of postmenopausal status only.e. All participants will undergo testing for HCVAb during Screening. Participants who are HCVAb 
positive will be reflex tested for HCV RNA. Participants who are HCVAb and HCV RNA positive are not eligible for the study. Participants who are HCVAb positive but HCV RNA negative will be 
considered eligible.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.
 
 
 
 
 
Interferon Gamma Release Assay
QFT-G test will be performed during screening. Blood sampling may include 3 mL up to 
10 mL of blood. Test should be performed in accordance with the product specific processing and analyzing instructions.CCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 6310.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and uni ntended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator. Any 
abnor mal laboratory  test results that meet any  of the conditions below must be 
recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of an y protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either an 
increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 64Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being stu died, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (soci al and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an event 
thathypothetically  might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing ho spitalization
In general, hospitalization signifies that the participant has been admitted (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or w as necessary , the 
AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 65d.Results in persistent or significant disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,
such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a Pfizer product of an infectious a gent, 
pathogenic or non -pathogenic, is considered serious.  
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a Pfizer product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations, such as significant 
medical events that may jeopardize the participant or may  require medical or 
surgical intervent ion to prevent one of the other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bron chospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to Pfizer Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonse rious AEs; and (3) exposure to the study  intervention under stud y during pregnancy  
or breastfeeding, and occupational exposure. 

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 66It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are
reported (whether or not 
there is an associated 
SAE).**
Environmental or 
occupational exposure to 
the product under stud y 
to a non -participant (not 
involving EDP or EDB).None. Exposure to a study 
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to Pfizer Safety 
using CT SAE Report Form and EDP Supplemental Form; if the EDP is associated with an SAE, then 
the SAE is reported to Pfizer Safety using the CT SAE Report Form. 
** EDB is reported to Pfizer Safety using the CT SAE Report Form which w ould also include details of any 
SAE that might be associated with the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational exposure are 
reported to Pfizer Safety using the CT SAE Report Form. 
When an AE or SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 67It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. 
Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive int ervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shopping for groceries or clothes, using the telephone, managing money , etc.
Severe: Severe or medically  significant but not immediately  life-threat ening; 
hospitalization or prolongation of hospitalization indicated; disabling, limiting self 
care ADL. Self care ADL refers to bathing, dressing and undressing, feeding self, 
using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a r elationship cannot 
be ruled out.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 68Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opinion of causality  in light of follow -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for report ing 
purposes, as defined b y the sponsor . In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  the 
sponsor ,to elucidate the nature and/or causalit y of the AE or SAE as full y as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -
up period, the investigator will provide Pfizer Safet y with a cop y of any 
postmortem findings, including histopathology .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 69New or updated informati on will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to Pfizer Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to preve nt the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site c an report this information on a paper SAE form (see 
next section) or to Pfizer Safety  by telephone.
SAE Reporting to Pfizer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the facsimile is not working , notification by  telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  overnight mail or 
courier service.
Initial not ification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 7010.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Not applicable .
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below i n Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a failure 
rate of <1% per 
year), with low user dependency, as described below during the 
intervention period and for at least 28days or 5 terminal half -lives plus 14 days 
(whichever duration is longer) after the last dose of study  intervention, which 
corresponds to the time needed to eliminate an y reproductive safety  risk of the study  
intervention .The investigator should evaluate the effectiveness of the contraceptive 
method in relationship to the first dose of stud y intervention .
A WOCBP agrees not to donate eggs (ova, oocy tes) for the purpose of reproduction during 
this period. The investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study  intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy .
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 71For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highl y effective contraception methods 
if they  wish to continue their HRT during the study .Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Contraceptive use b y me n or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependency 
1.Intrauterine device.
2.Bilateral tubal occlusio n (eg, bilateral tubal ligation) .
3.Vasectomized partner. 
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The spermatogenesis cy cle is approximately  90days.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 724.Sexual abstinence. 
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during th e entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant .

PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 73 
 
 
 
 
 
  
 
 
 
 
 
.CCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 7410.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments and 
Study Intervention Rechallenge Guidelines
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI. 
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in TBili ty pically  occurs while AST/ALT 
is/are still elevated above 3 ×ULN (eg, AST/ALT and TBili values will be elevated within 
the same lab oratory sample). In rare instances, by the time TBili elevations are detected, 
AST/AL T values might have decreased. This occurrence is still regarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and unde rlying conditions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and T Bilibaseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST O R ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 75Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results. This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurements of AST and AL T and TBili for suspected Hy ’s law 
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consi deration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consum ption, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all result s of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 7610.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by≥60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie,rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’ duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive ventricular 
complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of myocardial ischemia .
New -onset l eft bundle branch block (QRS >120 msec).
New -onset right bundle b ranch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with 1 or more pauses of at least 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 77Ventricular r hythms >30 seconds’ duration, including idioventricular rh ythm (heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR > 40bpm to <100 bpm),and 
monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm (such as
torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and Pfizer study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SA Es.

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 7810.8. Appendix 8: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
 ongoing/continuous event
-hCG a quantitative human chorionic gonadotropin
Abs absolute
ADL activities of daily  living
AE adverse event
ALC absolute ly mphocy te count
ALT alanine aminotransferase
ANC absolute neutrophil count
ARDS acute respiratory  distress sy ndrome
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC 24 area under the concentration -time curve from time 0 to 24 hours
AUC inf area under the plasma concentration -time profile from time 0 
extrapolated to infinite time
AUC last area under the plasma concentration -time profile from time zero to 
the time of the last quantifiable concentration (C last)
AUC tau area under the plasma concentration -time profile from time 0 to 
time tau, the dosing interval
AV atrioventricular
BBS Biospecimen Banking S ystem
BCRP breast cancer resistance protein
BID twice a day
BMI body  mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
14C a radioactive isotope of carbon
Clast last quantifiable concentration
Cmax maximum plasma concentration during the dosing interval
Cmin minimum observed concentration
CFR Code of Federal Regulations
CI confidence interval
CIA collagen induced arthritis
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI Chronic Kidney  Disease Epidemiology  Collaboration
CL/F apparent clearance
CMV cytomegalovirus

PF-06650833
Protocol B7921026Final Protocol, 29 July 2021
PFIZER CONFIDENTIAL
Page 79Abbreviation Term
CO 2 carbon dioxide (bicarbonate)
COVID-19 coronavirus disease 2019
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR clinical study report
CT clinical trial
CTMS clinical trial management system
CVw% within- participant coefficient of variation
CYP cytochrome P450
DDI drug-drug interaction 
DILI drug-induced liver injury
DMC data monitoring committee
EBV Epstein-Barr virus
EC ethics committee
EC 50 the concentration of a drug that gives half-maximal response
ECC Emergency Contact Card
ECG electrocardiogram
eCRF electronic case report form
EDB exposure during breastfeeding
EDP exposure during pregnancy
EE ethinyl estradiol
EFD embryo-fetal developmental
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
Emax the maximum effect
EU European Union
EudraCT European Clinical Trials Database
F bioavailability
Fa fraction absorbed
FACS fluorescent activated cell sorting
FSH follicle-stimulating hormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GI gastrointestinal
GLP Good Laboratory Practice
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCV hepatitis C virusCCI
PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 80Abbreviation Term
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therap y
HS hidradenitis suppurativa
HSV herpes simplex virus
IB investigator’s brochure
IC50 the concentration of an inhibitor where the response (or binding) is 
reduced b y half
ICD informed consent document
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ID identification
IGRA Interferon Gamma Release Assay
IND investigation al new drug 
INR international normalized ratio
IP investigational product
IPAL Investigational Product Accountability  Log
IQMP integrated qualit y management plan
IR immediate release
IRAK4 IL -1 receptor associated kinase 4
IRB institutional review board
IV intravenous
kel terminal phase rate constant
K2EDTA dipotassium ethy lenediaminetetraacetic acid
LBBB left bundle branch block
LFT liver function test
LN levonorgestrel
MAD multiple ascending dose
MATE multidrug and toxin extrusion protein
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MR modified release
mRNA messenger ribonucleic acid
msec millisecond
N/A not applicable
NIMP Non Investigational Medicinal Product
NOAEL no-observed -adverse -effect level
OAT organicanion transporter
OATP organic anion -transporting pol ypeptide
OC oral contraceptive

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 81Abbreviation Term
OCT organic cation transporter
PCR polymerase chain reaction
PCRU Pfizer Clinical Research Unit
PD pharmacod ynamic(s)
P-gp P-glycoprotein
PI principal investigator
PK pharmacokinetic(s)
PO by mouth
PPD purified protein derivative
PT prothrombin time
PTR peak -to-trough ratio
PVC premature v entricular contraction/complex
QD once dail y
QFT -G QuantiFERON -TB Gold IN-Tube
QID 4 times a day
QTc corrected QT
QTcF corrected QT (Fridericia method)
qual qualitative
RA rheumatoid arthritis
RBC red blood cell
RNA ribonucleic acid
SAD single ascending dose
SAE serious adverse event
SAP statistical analy sis plan
SARS -CoV -2 severe acute respiratory  syndrome coronavirus 2
SCr serum creatinine
SD standard deviation
SoA schedule of activities
SOC system organ class
SOP standard operating procedure
SRSD single reference safet y document
ST-T the ST segment and T-wave
SUL T sulfotransferase
SUSAR suspected unexpected serious adverse reaction
t½ terminal elimination half -life
Tmax Time for C max
TB tuberculosis
TBili total bilirubin
TBNK lymphocy te subsets (T cells, B cells, and NK cells)
TEAE treatment emergent adverse event
THC tetrah ydrocannabinol

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 82Abbreviation Term
TLR tool-like receptor
UGT uridine diphosphate -glucuronsy ltransferase
ULN upper limit of normal
US United States
VZV varicella zoster virus
WBC white blood cell
WOCBP woman /women of childbearing potential
WONCBP women of non -childbearing potential

PF-06650833
Protocol B7921026
Final Protocol ,29 July 2021
PFIZER CONFIDENTIAL
Page 8311. R EFERENCES
NONE. 
